Melanoma Clinical Trial
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Summary
The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma.
Full Description
A Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation Phase (Open-label, Ascending Single and Repeat Dose) and a Randomized, Masked Confirmatory Phase Designed to Evaluate the Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma.
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)
Have no evidence of metastatic disease confirmed by imaging
Be treatment naïve for IL/CM
Exclusion Criteria:
Have known contraindications or sensitivities to the study drug or laser
Active ocular disease
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 22 Locations for this study
Tucson Arizona, 85710, United States
Los Angeles California, 90095, United States
Palo Alto California, 94303, United States More Info
Contact
Atlanta Georgia, 30322, United States
Chicago Illinois, 60612, United States More Info
Contact
Iowa City Iowa, 52242, United States
Boston Massachusetts, 02114, United States More Info
Contact
Ann Arbor Michigan, 48105, United States More Info
Contact
Royal Oak Michigan, 48073, United States More Info
Contact
Minneapolis Minnesota, 55404, United States
New York New York, 10027, United States More Info
Contact
Oklahoma City Oklahoma, 73104, United States More Info
Contact
Portland Oregon, 97239, United States More Info
Contact
Philadelphia Pennsylvania, 19107, United States
Greenville South Carolina, 29605, United States More Info
Contact
Nashville Tennessee, 37203, United States More Info
Contact
Madison Wisconsin, 53705, United States More Info
Contact
How clear is this clinincal trial information?